Clinical Implications of "Atypia" on Biopsy: Possible Precursor to Lung Cancer?

Curr Oncol. 2021 Jul 6;28(4):2516-2522. doi: 10.3390/curroncol28040228.

Abstract

Background: It is common for biopsies of concerning pulmonary nodules to result in cytologic "atypia" on biopsy, which may represent a benign response or a false negative finding. This investigation evaluated time to diagnosis and factors which may predict an ultimate diagnosis of lung cancer in these patients with atypia cytology on lung nodule biopsy.

Methods: This retrospective study included patients of the Stony Brook Lung Cancer Evaluation Center who had a biopsy baseline diagnosis of atypia between 2010 and 2020 and were either diagnosed with cancer or remained disease free by the end of the observation period. Cox Proportional Hazard (CPH) Models were used to assess factor effects on outcomes.

Results: Among 106 patients with an initial diagnosis of atypia, 80 (75%) were diagnosed with lung cancer. Of those, over three-quarters were diagnosed within 6 months. The CPH models indicated that PET positivity (SUV ≥ 2.5) (HR = 1.74 (1.03, 2.94)), nodule size > 3.5 cm (HR = 2.83, 95% CI (1.47, 5.45)) and the presence of mixed ground glass opacities (HR = 2.15 (1.05, 4.43)) significantly increased risk of lung cancer.

Conclusion: Given the high conversion rate to cancer within 6 months, at least tight monitoring, if not repeat biopsy may be warranted during this time period for patients diagnosed with atypia.

Keywords: PET; atypia; cytology; lung cancer; lung nodule.

MeSH terms

  • Biopsy
  • Humans
  • Lung
  • Lung Neoplasms* / diagnosis
  • Retrospective Studies
  • Risk Factors